


Journey Medical Corporation

Corporate Overview



A Subsidiary of Fortress Biotech Inc.
(NASDAQ: FBIO)

The consolidation of Dermatology has created opportunities for start-ups with undervalued/non-promoted assets.



There are opportunities to secure undervalued dermatology assets currently owned by larger pharma companies.



A Subsidiary of Fortress Biotech Inc.
(NASDAQ: FBIO)

Journey Medical was formed to fill this market void and capture these opportunities

- **Journey Medical Corporation (JMC) was formed in October 2014 as a subsidiary of Fortress Biotech (NASDAQ: FBIO)**
 - Our focus is on identifying and strategically commercializing innovative, differentiated products through our efficient, potent sales and marketing model
- **The JMC team comprises of industry experts with decades of experience commercializing some of the most successful prescription dermatology brands**
 - Journey's sales relationships have enabled it to build a best-in-dermatology sales force capable of launching and growing brands in multiple dermatology specialties
 - Our market knowledge and experience helps Journey identify undervalued assets and future opportunities
- **Our team has played a key role in marketing and sales with some of the largest brands in prescription and aesthetic dermatology**
 - Across our collective careers in dermatology, our team has introduced new brands, built franchises, and extended growth for individual mature brands with over 1 million prescriptions per year



A Subsidiary of Fortress Biotech Inc.
(NASDAQ: FBIO)

Journey's Management has extensive experience and relationships in the dermatology industry



Claude Maraoui
President & CEO

- Claude has more than 30 years of experience in commercializing dermatology products. He was previously Vice President of Dermatology Sales at Medicis with a proven track record of success in leadership positions within the Sales & Marketing functions of both the prescription therapy and aesthetic businesses.



Robert Nevin
Executive VP Sales & Marketing

- Robert has more than 20 years of experience in pharmaceutical, lab and medical management. He has responsibility for sales, trade and managed care functions. Robert comes to Journey from The Dermatology Alliance where he served as Managing Partner for one of the nation's largest independent physician associations in the specialty of dermatology.



Ernest Galvan
Executive Director of Marketing

- Ernest has more than 25 years of experience in the dermatology pharmaceutical industry. With over 22 years in brand management and development, he has translated concepts into powerful marketing / brand solutions for a variety of dermatologic lines. Prior to Journey Medical, his experience includes Bristol Myers Squibb, Medicis, Ranbaxy, and Sun Dermatology.



Andrew Zwible
Director of Operations

- Andrew has 10 years of experience in Dermatology pharmaceuticals, working for Medicis and Valeant as a forecasting and analytics expert. He assisted with the buy-side \$455MM acquisition of Graceway Pharmaceuticals and the sell-side \$2.6B acquisition of Medicis.



A Subsidiary of Fortress Biotech Inc.
(NASDAQ: FBIO)

Our past Branded experience helps Journey make the most of its opportunities

TARGADOX[®]

(doxycycline hyclate USP) 50mg tablets

Exelderm[®]

(sulconazole nitrate) 1.0%

ABSORICA[®]
isotretinoin capsules

WITH LIDOSE[™] TECHNOLOGY

Luxamend[®]

Wound Cream

EURAX[®]

crothamiton USP 10%

Prescription itch relief

Ceracade[®]
Skin Emulsion

Ximino[™]

(minocycline hydrochloride)
Extended-Release Capsules

WITH INTELLIGENT DELIVERY

SOLODYN[®]
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

Vanos[®]
(flucinonide)
cream 0.1%

ZIANA[®]
(clindamycin phosphate 1.2%
and tretinoin 0.025%) Gel

LOPROX[®]
(ciclopirox) 0.77%

Restylane[®]
FAMILY OF INJECTABLE GELS

HALOG[®]

(Halcinonide, USP) 0.1%

APPLIED DESIGN.

DYNACIN[®]
(MINOCYCLINE
HCl TABLETS, USP)

SYNALAR[®]
(flucinalone acetonide)
Topical Solution, 0.01%

Zyclara[®]
(imiquimod) Cream
2.5% & 3.75%

LUSTRA[®]
(HYDROQUINONE CREAM USP, 4%)

Dysport[®]
abobotulinumtoxinA

PLEXION[®]
(benzoyl peroxide 2.5% and sulfur 4.0%)
Family of Products

KENALOG[®]
SPRAY with Spray Tube
Triamcinolone Acetonide
Topical Aerosol, USP (0.147mg/g)

TRIAZ[®]
(benzoyl peroxide)

■ Our team has played a key role in marketing and sales with some of the largest brands in prescription and aesthetic dermatology

- Across careers that collectively span several decades, have successfully marketed some of the largest brands in dermatology
- Launched new brands in the marketplace, built from the ground up
- Managed product lifecycles to extend revenue stream
- Created innovative first in class growth strategies


■ Proven track record of sales success (MRX, prior company of much of management team, sold for \$2.6B)

- We know dermatology and how to influence it!

JOURNEY[®]
MEDICAL CORPORATION

A Subsidiary of Fortress Biotech Inc.
(NASDAQ: FBIO)

Journey has quickly grown into a profitable company through an aggressive Product Launch Timeline



Targadox TRx Forecast




2017 TRx Actual

- 62,602

2018 TRx Forecast

- 125,342
- 100% growth



A Subsidiary of Fortress Biotech Inc.
(NASDAQ: FBIO)

Journey is developing an asset pipeline to expand upon its commercial success

- 1. Utilize Fortress Biotech's expertise in identifying, acquiring, and developing novel drugs to build a pipeline of Dermatology assets**
 - Dr. Lindsay Rosenwald has been a prolific and successful investor in the life sciences industry for over 20 years
- 2. Commercialize these assets using Journey's successful business model**



Experienced
Sales Force



Intense
Targeting
Algorithm



Specialty
Distribution
Network



Scalable Sales
and Promotion
Platform



Scientific and
Manufacturing
Expertise



Synergies with
Fortress Biotech



Journey Medical Roadmap



Phase 3: Product Development (Years 4-5)

- Current Gap

Phase 2: Product Launch (Years 2-3)

- Complete

Phase 1: Foundation (Year 1)

- Complete

- Journey has been successful at launching and promoting its first products
 - Operationally profitable in 2017
 - Experienced management team
 - High-caliber sales force
 - Expanding portfolio of products
- Journey's current gap before next-step strategic initiative is a product with long-term IP protection
 - Need product with strong intellectual property and high sales potential
 - Near term launch window